Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 7/20 | 0.39 |
| ▸ | SLC16A1 | P53985 | 6/20 | 0.39 |
| ▸ | OXTR | P30559 | 2/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697025 | 0.90 | TAS2R14 (0.40) | KMT2AALDH1A1LMNATAS2R14SLC16A3 | |
| SCHEMBL3698155 | 0.89 | HTR2C (0.41) | KMT2AALDH1A1LMNATAS2R14SLC16A3 | |
| SCHEMBL3702449 | 0.89 | ALDH1A1 (0.44) | KMT2AALDH1A1SLC16A3SLC16A1SMN1; SMN2 | |
| SCHEMBL4135860 | 0.88 | SLC16A3 (0.37) | KMT2AALDH1A1SLC16A3SLC16A1SMN1; SMN2 | |
| SCHEMBL3698156 | 0.88 | KMT2A (0.38) | KMT2AALDH1A1LMNATAS2R14SLC16A3 | |
| SCHEMBL3696956 | 0.88 | SLC16A3 (0.40) | KMT2AALDH1A1LMNASLC16A3SLC16A1 | |
| SCHEMBL3698987 | 0.84 | SLC16A3 (0.40) | SLC16A3SLC16A1 | |
| SCHEMBL4126098 | 0.84 | NAMPT (0.39) | KMT2ALMNASLC16A3SLC16A1NAMPT | |
| SCHEMBL4126447 | 0.83 | NAMPT (0.41) | KMT2AALDH1A1LMNATAS2R14SLC16A3 | |
| Fumaric Acid SCHEMBL3706208 | 0.83 | HTR2C (0.37) | KMT2AALDH1A1LMNATAS2R14SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | KMT2A 4776/4885ALDH1A1 1497/4885LMNA 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.